Compare · AZN vs MLTX
AZN vs MLTX
Side-by-side comparison of AstraZeneca PLC (AZN) and MoonLake Immunotherapeutics (MLTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and MLTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $261.92B, about 180.8x MLTX ($1.45B).
- Over the past year, AZN is down 10.3% and MLTX is down 63.3% - AZN leads by 52.9 points.
- AZN has been more active in the news (12 items in the past 4 weeks vs 3 for MLTX).
- Both have 25 recent analyst ratings on file.
- Company
- AstraZeneca PLC
- MoonLake Immunotherapeutics
- Price
- $168.85-0.24%
- $19.69+3.66%
- Market cap
- $261.92B
- $1.45B
- 1M return
- -5.56%
- +4.29%
- 1Y return
- -10.32%
- -63.26%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2020
- News (4w)
- 12
- 3
- Recent ratings
- 25
- 25
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest MLTX
- Chief Executive Officer Santos Da Silva Jorge sold $2,046,205 worth of Class A ordinary shares (102,225 units at $20.02) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 2,774,893 units (SEC Form 4)
- Chief Executive Officer Santos Da Silva Jorge sold $956,933 worth of Class A ordinary shares (47,775 units at $20.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 2,877,118 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 424B5 filed by MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
- Chief Financial Officer Bodenstedt Matthias sold $862,205 worth of Class A ordinary shares (39,120 units at $22.04) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,115,435 units (SEC Form 4)
- MoonLake Immunotherapeutics Announces Proposed Public Offering
- SEC Form 424B5 filed by MoonLake Immunotherapeutics
- SEC Form 4 filed by Director Bvf Partners L P/Il